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The most influential theory to explain the pathogenesis of Alzheimer’s disease (AD) has been the “Amyloid Cascade Hypothesis”
(ACH) first formulated in 1992. The ACH proposes that the deposition of β-amyloid (Aβ) is the initial pathological event in
AD leading to the formation of senile plaques (SPs) and then to neurofibrillary tangles (NFTs) death of neurons, and ultimately
dementia. This paper examines two questions regarding the ACH: (1) is there a relationship between the pathogenesis of SPs and
NFTs, and (2) what is the relationship of these lesions to disease pathogenesis? These questions are examined in relation to studies
of the morphology and molecular determinants of SPs and NFTs, the eﬀects of gene mutation, degeneration induced by head
injury, the eﬀects of experimentally induced brain lesions, transgenic studies, and the degeneration of anatomical pathways. It was
concluded that SPs and NFTs develop independently and may be the products rather than the causes of neurodegeneration in
AD. A modification to the ACH is proposed which may better explain the pathogenesis of AD, especially of late-onset cases of the
disease.
1. Introduction
Ever since the first description of presenile dementia by
Alzheimer in 1907 [1], senile plaques (SPs) and neurofib-
rillary tangles (NFTs) have been regarded as the “signature”
pathological lesions of Alzheimer’s disease (AD) [2–4].
AD became a nosological entity in 1910 and was named
after Alzheimer by Kraepelin based on the clinical and
pathological description of the original cases. Of the two
original cases described by Alzheimer, however, both had
numerous SPs but only one of the cases had significant
numbers of NFTs [5], thus creating a controversy as to the
relative significance of the two lesions that still persists today.
Studies of the molecular composition of the SPs played
a critical role in the development of hypotheses as to the
pathogenesis of AD. Hence, the discovery of β-amyloid (Aβ)
as the most important molecular constituent of the SPs
[6] resulted in the formulation of the “Amyloid Cascade
Hypothesis” (ACH), the most important model of the
molecular pathology of AD developed over the last 18 years
[7]. Essentially, the ACH proposes that the deposition of
Aβ (Figure 1) is the initial pathological event in the disease
leading to the formation of NFTs, cell death, and ultimately
dementia. Nevertheless, there are observations that are
diﬃcult to reconcile with the hypothesis. For example, in
transgenic mice, genes overexpressing amyloid precursor
protein (APP) do not produce the predicted cascade [8,
9]. Furthermore, SPs and NFTs appear to be separated in
the brain both temporally [9, 10] and spatially [11]. The
uncertainty as to the significance of SPs and NFTs in AD has
led to alternative models being proposed, especially in late-
onset cases, based on perturbation of vesicular traﬃcking
at synapses, disruption of the cytoskeletal network, or the
distribution of membrane cholesterol [12]. Some authors
have even suggested that SPs/NFTs may be the reactive
products of neurodegeneration, arising as a consequence of
oxidative stress [13], and that the proteins involved in their
formation are protective in function [14]. These observations
suggest a more complex relationship between SPs and NFTs
and the pathogenesis of AD and, therefore, that a reappraisal
of the ACH may be necessary.
This paper examines two questions regarding the ACH:
(1) is there a relationship between the pathogenesis of SPs
and NFTs, and (2) what is the relationship of these lesions
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Figure 1: Extensive β-amyloid (Aβ) deposition in gyri of the
temporal lobe in a case of Alzheimer’s disease (AD) (Aβ immuno-
histochemistry, bar = 1mm).
to disease pathogenesis? These questions are discussed with
reference to (1) studies of the morphology and molecular
composition of SPs and NFTs, (2) studies of the eﬀects
of gene mutation, (3) studies of head injury patients, (4)
experimental studies involving brain lesions and transgenes,
and (5) studies of the degeneration of anatomical pathways.
2. The “Amyloid Cascade Hypothesis” (ACH)
Two key observations resulted in the original formulation
of the ACH [7] (Figure 2). First, the discovery of Aβ as
the most important molecular constituent of the SPs [6]
drew attention to the importance of these amyloid peptides
in AD. Second, mutations of the APP gene [15, 16] and,
subsequently, of the presenilin genes (PSEN1/2) [17, 18] were
directly linked to cases of familial AD (FAD). Hence, the
presence of Aβ within SPs was regarded as the residue of
the eﬀect of these pathogenic gene mutations and which, via
the accumulation of toxic and insoluble Aβ peptides, led to
cell death and dementia. Since the pathological phenotype
of FAD is similar, apart from age of onset, to that of the
more common late-onset, sporadic AD (SAD) [19–21], it
was assumed that a similar mechanism, via genetic risk
factors and/or environmental factors, could explain the
pathogenesis of all cases of AD [22].
Evidence supporting the ACH comes from several
sources. First, experiments using transgenic mice expressing
high levels of APP result in Aβ deposition, synaptic loss,
and gliosis [23]. Second, FAD caused by the substitution of
valine by isoleucine at codon 717 of the APP gene also has
significant numbers of NFTs thus supporting a link between
APP and the cytoskeleton [24]. Third, cases linked to PSEN1
have greater numbers of SPs and NFTs compared with cases
of sporadic AD suggesting that PSEN1 may increase tau
deposition [25].
There have been several attempts to establish a mech-
anism by which the deposition of Aβ directly leads to
the formation of NFTs but none have become univer-
sally accepted. First, Giasson et al. [26] concluded that
Aβ promoted the formation of intracellular tau, although
the mechanism of this interaction was uncertain. Second,
attempts have been made to show that there is a synergistic
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Figure 2: The original Amyloid Cascade Hypothesis (ACH) [7].
Aβ: β-amyloid, APOE: apolipoprotein E, APP: amyloid precursor
protein, PSEN1/2: presenilin genes 1 and 2, NFTs: neurofibrillary
tangles.
interaction between NFTs and Aβ [27, 28]. Third, when
fetal rat hippocampal neurons and human cortical neurons
were treated with Aβ, fibrillar forms of Aβ could apparently
induce tau phosphorylation [29]. It was concluded that
amyloid fibril formation might alter the phosphorylation
state of tau resulting in the loss of microtubule-binding
capacity. Fourth, Pe´rez et al. [30] showed that Aβ25−35 could
induce the aggregation of tau proteins and that a decrease
in aggregation of Aβ was induced by tau peptides. Hence,
aggregation of tau may be associated with disassembly of Aβ
which could explain the lack of spatial correlation of the SPs
and NFTs [11].
3. Limitations of the ACH
There are two major objections regarding the ACH as
originally formulated. First, SPs and NFTs may be reactive
products resulting from neurodegeneration in AD rather
than being its cause [31] and, second there is no generally
accepted mechanism to explain how the deposition of Aβ
leads to the formation of NFTs.
Is the Formation of Aβ and Tau a Reactive Process?. In
survivors of head injury, APP is found in neuronal perikarya
and in dystrophic neurites surrounding Aβ deposits, similar
pathological features to AD [32]. The processing of APP
into Aβ in these cases occurs within the synaptic terminal
fold of the axons, the presence of glial cells not being
necessary for the conversion. Hence, the production of
APP may be a response of the brain to neuronal injury
[32]. Subsequently, it was shown that specific neurons in
the medial temporal lobe secreted large quantities of APP
and that there were more APP-immunoreactive neurons in
these areas in head injury patients [33]. Hence, increased
expression of APP in head trauma cases may be an acute-
phase response to neuronal injury [34], the overexpression
of APP leading to the deposition of Aβ. This conclusion
is supported by the observation that several acute-phase
proteins are localised within the diﬀerent morphological
forms of Aβ deposit, including diﬀuse, primitive, and classic
deposits (Table 1), for example, amyloid-P, complement
factors, and α-antichymotrypsin [35]. Furthermore, Regland
and Gottfries [36] proposed that, in AD, APP was involved in
disease processes secondarily to help maintain cell function.
Hence, APP may maintain neuronal growth and survival,
and its putative neurotrophic action is supported by the
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Table 1: Molecular composition of β-amyloid (Aβ) deposits in Alzheimer’s disease (AD).
Deposit subtype Molecular composition
Diﬀuse Aβ APP (lacking C terminus), Aβ42/43 apolipoprotein E, α1-antichymotrypsin, HSPG, complement proteins (C1q,
C3, C4), amyloid-P
Primitive Aβ APP (N & C-terminal), Aβ42/43, free and conjugated ubiquitin, PHF antigen, phosphorylated tau,
chromogranin-A, bFGF, apolipoprotein E, interleukin-6
Classic Aβ
Aβ42/43 “core”, α-synuclein “ring”, Aβ40, actin, tubulin, phosphorylated tau, NF-protein, CAM, chromogranin-A
“ring”, α2-macroglobulin, complement proteins “core”, immunoglobulins “core”, amyloid-P,
α1-antichymotrypsin, antitrypsin, antithrombin III, apolipoprotein E and D “core”, bFGF, PrP,
silicon/aluminium “core”, interleukin-6 “ring”
Aβ: β-amyloid, APP: amyloid precursor protein, bFGF: basic fibroblast growth factor, CAM: cell adhesion molecule, HSPG: heparan suphate proteoglycan,
NF-protein: neurofilament protein, PHF: paired helical filament, and PrP: prion protein.
observation that APP shares structural features with the
precursor for epidermal growth factor [36]. Furthermore,
NFTs may be part of the neurons response to injury [37].
Hence, studies of head injury patients support the hypothesis
that Aβ deposition and NFTs formation could be reactive
processes.
The results of animal experiments also suggest that the
formation of Aβ may be a reactive process. Experimental
lesions that damage the nucleus basalis in the brain of the
rat elevate APP synthesis in the cerebral cortex suggesting
that the production of APP could be a specific response to
loss of functional innervation of the cortex [38]. Chemically
induced lesions of the brain produce similar results. For
example, lesions of the nucleus basalis using N-methyl
D-aspartate (NMDA) elevate APP synthesis in cortical
polysomes [38], and, in areas of brain damaged by kainite
[39], APP695 was recorded in dystrophic neurites near
to the lesion. In addition, intrathecal or intraparenchymal
injections of a toxin induced APP in hippocampal neurons
subsequent to neuronal damage [40].
Lesion experiments may also induce pathological
changes implicated in the development of NFTs. Denervation
of the dopamine pathways and septal lesions aﬀecting both
the cholinergic system and γ-aminobutyric acid (GABA)
neurons projecting to the dentate gyrus results in a loss of
dendritic microtubule-associated protein 2 (MAP2) and the
appearance of tau-immunoreactive dentate gyrus granule
cells [41]. It was concluded from this experiment that
denervation causes transsynaptic changes in dentate gyrus
neurons and that these changes may represent a precursor
stage to NFTs formation.
Is the Formation of NFT Related to Aβ?. A number of studies
have suggested that SPs and NFTs occur in distinct but
independently distributed patterns in AD [11, 42]. Studies
of the spatial patterns of SPs and NFTs show them to
be clustered with, in a significant proportion of cortical
areas, a regular distribution of the clusters parallel to the
pia mater [43]. The clusters of SPs and NFTs, however,
are distributed independently of each other, that is, neither
in nor out of phase, which would not support a direct
pathogenic link between them. In addition, SPs and NFTs
appear to be separated in the brain temporally [10]. Indeed,
in the entorhinal cortex, the NFTs may actually precede the
appearance of SPs [9].
In transgenic experiments [44], the presence of APP
mutations alone or in combination with PSEN1 can induce
Aβ deposits in normal brain, but apart from some evidence
for hyperphosphorylated tau in neurites associated with
the plaques, do not appear to induce tau pathology or a
significant inflammatory response. Hence, the presence of
tau transgenes in the form of a triple model appears to be
necessary to replicate AD pathology.
4. Modification of the ACH
A modification of the original ACH which incorporates
these concerns is presented in Figure 3. In this modified
hypothesis, the essential trigger to the development of AD
is ageing of the brain and associated risk factors such
as head trauma, vascular disease, and systemic disease,
collectively referred to as the “allostatic load” [45]. These
factors exacerbate processes leading to cell death. As neurons
degenerate, various proteins are upregulated leading to the
formation of extracellular Aβ deposits and intracellular tau,
the latter resulting in the development of NFTs. These
reaction products may be toxic and initiate a further phase
of secondary degeneration that accelerates the neuronal loss
leading to dementia. In this modified hypothesis, genetic
factors, rather than initiating disease, indirectly influence
the formation and composition of peptides formed when
neurons degenerate. Hence, the modified ACH incorpo-
rates information suggesting a more complex relationship
between SPs and NFTs and proposes that the lesions are
essentially reactive rather than causal.
5. Discussion
5.1. Predictions of the Modified ACH. The modified ACH
suggests that it is ageing and the diseases associated with
ageing that provide the “trigger” initiating the “cascade” of
events leading to AD rather than the initial deposition of
Aβ. The modified hypothesis makes a number of predic-
tions. First, the hypothesis predicts that significant signs of
neuronal degeneration in AD should precede those of Aβ
deposition and the eﬀect of Aβ is secondary rather than
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Figure 3: A modification of the Amyloid Cascade Hypothesis
(ACH). Aβ: β-amyloid, APOE: apolipoprotein E, APP: amyloid
precursor protein, PSEN1/2: presenilin genes 1 and 2, NFTs: neu-
rofibrillary tangles, and SPs: senile plaques.
primary in causing neurodegeneration. Second, it predicts
that the pathogeneses of SPs and NFTs are not directly linked
and the two lesions essentially arise independently. Third,
in transgenic experiments, the eﬀect of the transgene will
be age-dependent. In a model which incorporates an APP,
V717I mutation, for example, there was an age-related loss of
pyramidal neurons in the hippocampus CA sectors included
at sites devoid of plaque deposition [46] consistent with this
prediction.
5.2. Predictions of the Modified ACH. First, the modified
hypothesis suggests that SAD is not a disease linked primarily
to defective genes but a complex syndrome dependant on
the rate of ageing and indirectly influenced by genetic
risk factors and the environment. Second, the hypothesis
questions whether the presence, distribution, and molecular
determinants of SPs and/or NFTs (Table 1) should continue
to play a primary role in the pathological diagnosis of
AD. There are two problems that need to be considered.
If SPs/NFTs are the products of brain degeneration and
not its cause, then they may represent relatively late stages
in pathogenesis. Hence, there may be cases of AD that
are diﬃcult to classify because they may have insuﬃcient
numbers of SPs and NFTs or exhibit early developmental
stages of these pathologies. In addition, if SPs and NFTs
represent the consequences of specific types of neurode-
generation rather than being characteristic of a particular
disease, then there are likely to be many cases that show
combinations of pathological features; that is, there will be
a considerable degree of overlap between diﬀerent disorders.
Numerous examples of such cases have been reported in the
literature, for example, dementia with Lewy bodies (DLB)
with associated AD pathology, Creutzfeldt-Jakob disease
(CJD) with AD, and Pick’s disease (PkD) with AD, and
these cases are often diﬃcult to classify within the existing
system [47]. Third, assuming that the role of SPs and NFTs
in the pathogenesis of AD is at least controversial, should
significant eﬀort continue to be devoted to immunotherapy
and other treatments designed to remove Aβ from the brain?
Such treatments could be beneficial in limiting the degree
of secondary degeneration induced by Aβ. Nevertheless, Aβ
might be beneficial to the nervous system by promoting
neurogenesis [48] and having a range of other protective
functions [49]. Hence, excessive removal of Aβ could reduce
chelation within the brain and result in enhanced oxidative
stress [13].
6. Conclusions
Since 1992, the ACH has played an influential role in
explaining the etiology and pathogenesis of Alzheimer’s
disease (AD). It proposes that the deposition of β-amyloid
(Aβ) is the initial pathological event in AD leading to the
formation of senile plaques (SPs), and then to neurofibrillary
tangles (NFTs), death of neurons, and ultimately dementia.
There are, however, two limitations of the ACH: (1) SP and
NFT may develop independently, and (2) SPs and NFTs may
be the products rather than the causes of neurodegeneration
in AD. A modification to the ACH is proposed which may
better explain the pathogenesis of AD, especially in late-onset
cases of the disease. The modifications to the ACH make a
number of predictions which could be usefully investigated.
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